Questions About Cancer? 1-800-4-CANCER
  • View entire document
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Chronic Lymphocytic Leukemia Treatment (PDQ®)

Changes to This Summary (12/05/2014)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Stage I, II, III, and IV Chronic Lymphocytic Leukemia

Added Strati et al. as reference 7.

Added text to state that obinutuzumab is a human anti-CD20 monoclonal antibody treatment option and provided statistics from a randomized prospective trial (NCT01010061) of 781 previously untreated patients with coexisting medical problems who were randomly assigned to chlorambucil plus obinutuzumab versus chlorambucil plus rituximab versus chlorambucil alone (cited Goede et al. as reference 16 and level of evidence (LOE) 1iiA).

Added text to state that idelalisib is an oral inhibitor of the delta isoform of the phosphatidylinositol 3-kinase and provided statistics from a randomized, double-blind, prospective trial (NCT01539512) of 220 patients treated mainly with fludarabine-based regimens who had coexisting medical problems and received rituximab plus idelalisib versus rituximab plus placebo (cited Furman et al. as reference 17 and LOE 1iA).

Added O'Brien et al. as reference 19.

Added text to state that a series of 90 patients with relapsed or refractory CLL who underwent allogeneic stem cell transplantation reported a 58% 6-year overall survival rate and a 38% 6-year event-free survival rate, which included those patients with the worst prognostic factors (cited Dreger et al. as reference 92 and LOE 3iiiD).

Revised text to state that ongoing clinical trials are testing the concept of T-cells directed at specific antigen targets with engineered chimeric–antigen receptors (cited Maus et al. as reference 94).

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

  • Updated: December 5, 2014